Galmed Pharmaceuticals Ltd
GLMD0.880USD
+0.000+0.03%
收盘 12/24, 13:00（美东）报价延迟15分钟
4.82M总市值
亏损市盈率 TTM
关于 Galmed Pharmaceuticals Ltd 公司
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Galmed Pharmaceuticals Ltd简介
公司代码GLMD
公司名称Galmed Pharmaceuticals Ltd
上市日期Mar 13, 2014
CEOBaharaff (Allen)
员工数量3
证券类型Ordinary Share
年结日Mar 13
公司地址16 Tiomkin Street
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编6578317
电话97236938448
网址https://www.galmedpharma.com
公司代码GLMD
上市日期Mar 13, 2014
CEOBaharaff (Allen)
Galmed Pharmaceuticals Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
3.12K
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Citadel Advisors LLC
0.71%
Baharaff (Allen)
0.52%
Two Sigma Investments, LP
0.30%
Nehemya (Guy)
0.09%
Stenzler (Yohai)
0.09%
其他
98.30%
持股股东
持股股东
占比
Citadel Advisors LLC
0.71%
Baharaff (Allen)
0.52%
Two Sigma Investments, LP
0.30%
Nehemya (Guy)
0.09%
Stenzler (Yohai)
0.09%
其他
98.30%
股东类型
持股股东
占比
Hedge Fund
1.00%
Individual Investor
0.92%
Investment Advisor
0.04%
其他
98.04%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
29
75.58K
1.38%
-16.12K
2025Q2
36
135.24K
2.48%
+20.85K
2025Q1
40
122.99K
5.45%
+7.20K
2024Q4
44
74.98K
4.98%
+4.09K
2024Q3
46
26.83K
4.31%
-41.91K
2024Q2
47
54.30K
10.41%
+4.14K
2024Q1
52
35.65K
7.07%
-49.52K
2023Q4
54
66.85K
19.98%
-30.97K
2023Q3
59
78.73K
21.96%
+19.78K
2023Q2
57
33.03K
13.93%
-6.52K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baharaff (Allen)
36.94K
0.67%
+8.83K
+31.44%
Mar 21, 2025
Nehemya (Guy)
6.28K
0.11%
+6.25K
+20164.52%
Mar 21, 2025
Stenzler (Yohai)
6.28K
0.11%
+6.25K
+20164.52%
Mar 21, 2025
Cohen (Doron)
6.25K
0.11%
+6.23K
+36664.71%
Mar 21, 2025
Nir (Shmuel)
3.40K
0.06%
+3.12K
+1148.16%
Mar 21, 2025
Sidransky (David)
3.12K
0.06%
+3.08K
+7338.10%
Mar 21, 2025
Poshinski (Amir)
3.12K
0.06%
+3.12K
--
Mar 21, 2025
Nomura Investment Management Business Trust
1.70K
0.03%
--
--
Jul 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
公告日期
类型
比率
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
常见问题
Galmed Pharmaceuticals Ltd的前五大股东是谁？
Galmed Pharmaceuticals Ltd 的前五大股东如下：
Baharaff (Allen)持有股份：36.94K，占总股份比例：0.67%。
Nehemya (Guy)持有股份：6.28K，占总股份比例：0.11%。
Stenzler (Yohai)持有股份：6.28K，占总股份比例：0.11%。
Cohen (Doron)持有股份：6.25K，占总股份比例：0.11%。
Nir (Shmuel)持有股份：3.40K，占总股份比例：0.06%。
Baharaff (Allen)持有股份：36.94K，占总股份比例：0.67%。
Nehemya (Guy)持有股份：6.28K，占总股份比例：0.11%。
Stenzler (Yohai)持有股份：6.28K，占总股份比例：0.11%。
Cohen (Doron)持有股份：6.25K，占总股份比例：0.11%。
Nir (Shmuel)持有股份：3.40K，占总股份比例：0.06%。
Galmed Pharmaceuticals Ltd的前三大股东类型是什么？
Galmed Pharmaceuticals Ltd 的前三大股东类型分别是：
Citadel Advisors LLC
Baharaff (Allen)
Two Sigma Investments, LP
Citadel Advisors LLC
Baharaff (Allen)
Two Sigma Investments, LP
有多少机构持有Galmed Pharmaceuticals Ltd(GLMD)的股份？
截至2025Q3，共有29家机构持有Galmed Pharmaceuticals Ltd的股份，合计持有的股份价值约为75.58K，占公司总股份的1.38%。与2025Q2相比，机构持股有所增加，增幅为-1.10%。
哪个业务部门对Galmed Pharmaceuticals Ltd的收入贡献最大？
在--，--业务部门对Galmed Pharmaceuticals Ltd的收入贡献最大，创收--，占总收入的--%。
